Nothing Special   »   [go: up one dir, main page]

MX2016014753A - Tratamiento de cancer de pulmon con el uso de una combinacion de un anticuerpo de muerte anti-programada 1 (anti-pd-1) y otro agente anti-cancerigeno. - Google Patents

Tratamiento de cancer de pulmon con el uso de una combinacion de un anticuerpo de muerte anti-programada 1 (anti-pd-1) y otro agente anti-cancerigeno.

Info

Publication number
MX2016014753A
MX2016014753A MX2016014753A MX2016014753A MX2016014753A MX 2016014753 A MX2016014753 A MX 2016014753A MX 2016014753 A MX2016014753 A MX 2016014753A MX 2016014753 A MX2016014753 A MX 2016014753A MX 2016014753 A MX2016014753 A MX 2016014753A
Authority
MX
Mexico
Prior art keywords
antibody
cancer
cancer agent
lung cancer
treatment
Prior art date
Application number
MX2016014753A
Other languages
English (en)
Inventor
Feltquate David
C Chen Allen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2016014753A publication Critical patent/MX2016014753A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Endocrinology (AREA)

Abstract

La presente invención se refiere a un método para tratar un sujeto afligido con un cáncer de pulmón, en el cual el método comprende administrar al sujeto cantidades terapéuticamente efectivas de: (a) un agente anti-cancerígeno el cual es un anticuerpo o una porción del mismo de unión al antígeno que se une específicamente a un receptor de Muerte Programada 1 (PD-1) e inhibe la actividad de PD-1; y (b) otro agente anti-cancerígeno. El otro agente anti-cancerígeno puede ser una quimioterapia doble a base de platino, un inhibidor de tirosina cinasa dirigido a EGFR, un anticuerpo anti-VEGF, un anticuerpo del Antígeno 4 del Linfocito T anti-Citotóxico (CTLA-4), o cualquier otra terapia usada para tratar cáncer de pulmón en la técnica o descrito en la presente.
MX2016014753A 2014-05-15 2015-05-15 Tratamiento de cancer de pulmon con el uso de una combinacion de un anticuerpo de muerte anti-programada 1 (anti-pd-1) y otro agente anti-cancerigeno. MX2016014753A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461993917P 2014-05-15 2014-05-15
US201462005640P 2014-05-30 2014-05-30
US201562152669P 2015-04-24 2015-04-24
PCT/US2015/031241 WO2015176033A1 (en) 2014-05-15 2015-05-15 Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent

Publications (1)

Publication Number Publication Date
MX2016014753A true MX2016014753A (es) 2017-03-06

Family

ID=53276304

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016014753A MX2016014753A (es) 2014-05-15 2015-05-15 Tratamiento de cancer de pulmon con el uso de una combinacion de un anticuerpo de muerte anti-programada 1 (anti-pd-1) y otro agente anti-cancerigeno.
MX2022004000A MX2022004000A (es) 2014-05-15 2016-11-10 Uso de un anticuerpo de muerte anti-programada 1 (anti-pd-1) en combinacion con una quimioterapia doble a base de platino (pt-dc) para el tratamiento de cancer de pulmon.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022004000A MX2022004000A (es) 2014-05-15 2016-11-10 Uso de un anticuerpo de muerte anti-programada 1 (anti-pd-1) en combinacion con una quimioterapia doble a base de platino (pt-dc) para el tratamiento de cancer de pulmon.

Country Status (10)

Country Link
US (3) US20170158776A1 (es)
EP (2) EP3142697A1 (es)
JP (1) JP2017515859A (es)
KR (2) KR20230144099A (es)
CN (2) CN106714839A (es)
BR (1) BR112016026559A8 (es)
CA (1) CA2949121A1 (es)
MX (2) MX2016014753A (es)
RU (1) RU2695332C2 (es)
WO (1) WO2015176033A1 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
JP6502959B2 (ja) 2013-12-12 2019-04-17 上海恒瑞医薬有限公司 Ｐｄ−１抗体、その抗原結合性断片及びそれらの医学的使用
MX2016007887A (es) 2013-12-17 2016-10-28 Genentech Inc Metodos de tratamiento de canceres positivos a her2 usando antagonistas de union del eje de pd-1 y anticuerpos anti-her2.
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
SI3102605T1 (sl) 2014-02-04 2019-04-30 Pfizer Inc. Kombinacija PD-1 antagonista in VEGFR inhibitorja za zdravljenje raka
EP3138555B1 (en) 2014-04-30 2020-10-28 FUJIFILM Corporation Liposome composition and production method therefor
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
WO2016040892A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies
KR20170101925A (ko) * 2014-12-02 2017-09-06 셀진 코포레이션 병용 요법
EP4279087A3 (en) 2015-02-26 2024-01-31 Merck Patent GmbH Pd-1 / pd-l1 inhibitors for the treatment of cancer
JP2018515474A (ja) 2015-04-28 2018-06-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
PE20180673A1 (es) * 2015-06-01 2018-04-19 Univ Chicago Tratamiento contra el cancer por manipulacion de la microflora comensal
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
IL256245B (en) 2015-06-16 2022-09-01 Merck Patent Gmbh Treatments that combine a pd-l1 antagonist
CN107771076A (zh) 2015-06-17 2018-03-06 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
AU2016294440B2 (en) 2015-07-13 2022-10-13 Cytomx Therapeutics, Inc Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof
CN107847574B (zh) 2015-07-30 2023-05-23 宏观基因有限公司 Pd-1结合分子和其使用方法
PE20181018A1 (es) 2015-08-11 2018-06-26 Wuxi Biologics Cayman Inc Anticuerpos anti-pd-1 novedosos
SG10201913276WA (en) 2015-09-01 2020-02-27 Agenus Inc Anti-pd-1 antibodies and methods of use thereof
US20180231554A1 (en) * 2015-09-04 2018-08-16 The Brigham And Women's Hospital, Inc. Programmed cell death (pd-1) inhibitor therapy for patients with pd-1-expressing cancers
EP3377534A1 (en) 2015-11-18 2018-09-26 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody
JP6925337B2 (ja) * 2015-12-07 2021-08-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗ｐｄ−ｌ１抗体アベルマブを含む水性医薬製剤
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
WO2017112775A1 (en) 2015-12-22 2017-06-29 Regeneron Pharmaceuticals, Inc. Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
US11710539B2 (en) 2016-02-01 2023-07-25 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
JP7014724B2 (ja) * 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Ｆａｂ免疫グロブリンおよびその使用
EP3213768A1 (en) * 2016-03-01 2017-09-06 LODOCO CLINICAL Kft Combination of low dose immune checkpoint blockade with high dose il-2 for treating metastatic cancer
US11209441B2 (en) 2016-04-05 2021-12-28 Bristol-Myers Squibb Company Cytokine profiling analysis
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
US11285274B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device
US11285283B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Methods for generating and delivering droplets to the pulmonary system using a droplet delivery device
US11285285B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment
US11285284B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Methods for treatment of pulmonary lung diseases with improved therapeutic efficacy and improved dose efficiency
TWI755395B (zh) 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
US20190183972A1 (en) * 2016-06-03 2019-06-20 Imclone Llc Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
KR20190019121A (ko) * 2016-06-17 2019-02-26 오사카 유니버시티 종양 내 정맥 형성 촉진제
JP2019527204A (ja) * 2016-07-01 2019-09-26 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抑制性免疫受容体阻害方法および組成物
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN110036030A (zh) 2016-09-26 2019-07-19 英克隆有限责任公司 癌症的组合疗法
KR20190062515A (ko) 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
KR20240023677A (ko) 2016-12-05 2024-02-22 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
AU2017373945A1 (en) * 2016-12-07 2019-06-20 Agenus Inc. Antibodies and methods of use thereof
MX2019006340A (es) 2016-12-07 2019-11-07 Agenus Inc Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
WO2018107244A1 (en) * 2016-12-15 2018-06-21 Progen Pg500 Series Pty Ltd Composition and uses thereof
WO2018129301A1 (en) 2017-01-05 2018-07-12 Biodesix, Inc. Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups
CA3053239A1 (en) * 2017-02-17 2018-08-23 George Todaro Use of tgf alpha for the treatment of diseases and disorders
US11292842B2 (en) * 2017-02-21 2022-04-05 Regeneron Pharmaceuticals, Inc. Anti-PD-1 antibodies for treatment of lung cancer
EP3634552A4 (en) 2017-05-19 2021-03-03 Pneuma Respiratory, Inc. DRY POWDER ADMINISTRATION DEVICE AND METHODS OF USE
BR112019018759A2 (pt) * 2017-05-30 2020-05-05 Bristol-Myers Squibb Company composições compreendendo uma combinação de um anticorpo anti-lag-3, um inibidor da via pd-1, e um agente imunoterápico
WO2019023786A1 (en) 2017-08-01 2019-02-07 University Health Network COMBINED THERAPIES FOR THE INHIBITION OF TTK PROTEIN KINASE
US10927175B2 (en) * 2017-08-08 2021-02-23 Sun Jet Biotechnology Inc. Method for treating cancer
EP3679046B1 (en) * 2017-09-08 2023-11-08 Promontory Therapeutics Inc. Phosphaplatin compounds as immuno-modulatory agents and therapeutic uses thereof
KR20200061382A (ko) * 2017-09-29 2020-06-02 브리스톨-마이어스 스큅 컴퍼니 암을 치료하기 위한 조성물 및 방법
CN118203735A (zh) 2017-10-04 2024-06-18 精呼吸股份有限公司 电子呼吸致动式直线型液滴输送装置及其使用方法
EP4344719A3 (en) 2017-10-17 2024-06-05 Pneuma Respiratory, Inc. Nasal drug delivery apparatus and methods of use
JP2021502178A (ja) 2017-11-08 2021-01-28 ニューマ・リスパイラトリー・インコーポレイテッド 小容積アンプルを有して呼吸により電気的に作動するインライン液滴送達装置および使用方法
EP3737444A4 (en) * 2018-01-08 2021-10-13 Pneuma Respiratory, Inc. TREATMENT OF LUNG CANCERS USING AN ELECTRONIC RESPIRATION-ACTED DROPLET DELIVERY DEVICE
KR102089241B1 (ko) * 2018-02-05 2020-03-16 한국과학기술원 암 환자에서 면역 치료 효과를 예측하는 방법
US12094587B2 (en) 2018-03-29 2024-09-17 Biodesix, Inc. Apparatus and method for identification of primary immune resistance in cancer patients
WO2019210848A1 (en) 2018-05-03 2019-11-07 Shanghai Epimab Biotherapeutics Co., Ltd. High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom
DK3811949T3 (da) * 2018-06-20 2024-10-07 Fujifilm Corp Kombineret medicin omfattende gemcitabin-indkapslet liposomsammensætning og immun-checkpoint-blokade
CN112839644A (zh) * 2018-07-18 2021-05-25 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂、抗代谢物和铂剂治疗肺癌的方法
JP2022505647A (ja) * 2018-10-23 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍の処置方法
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CA3131259A1 (en) * 2019-02-28 2020-09-03 Shattuck Labs, Inc. Combination therapies
CN111617243B (zh) * 2019-02-28 2023-12-19 正大天晴药业集团股份有限公司 喹啉衍生物与抗体的药物组合
EP3938399A4 (en) * 2019-03-13 2023-04-12 The Brigham & Women's Hospital, Inc. TARGETED REGULATORY B CELLS AND THEIR REGULATORS FOR CANCER IMMUNOTHERAPY
US20220411507A1 (en) * 2019-03-13 2022-12-29 Merck Sharp & Dohme Corp. Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents
WO2020198510A1 (en) * 2019-03-28 2020-10-01 Sierra Oncology, Inc. Methods of treating cancer with chk1 inhibitors
MX2021011810A (es) * 2019-03-29 2021-10-26 Astrazeneca Ab Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.
EP3986439A4 (en) * 2019-06-21 2023-10-04 University of Kansas COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF BRAIN DISEASES
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
WO2021126906A1 (en) * 2019-12-20 2021-06-24 Merck Sharp & Dohme Corp. Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
WO2022006514A1 (en) * 2020-07-02 2022-01-06 Gopath Laboratories Llc Immune profiling and methods of using same to predict responsiveness to an immunotherapy and treat cancer
MX2023002278A (es) * 2020-08-28 2023-03-10 Shanghai Junshi Biosciences Co Ltd Uso de un anticuerpo anti-pd-1 y un farmaco antineoplasico citotoxico en el tratamiento del cancer de pulmon no microcitico.
JP2024525200A (ja) 2021-06-22 2024-07-10 ニューマ・リスパイラトリー・インコーポレイテッド プッシュ排出を用いる液滴送達デバイス
US20230322928A1 (en) * 2022-03-07 2023-10-12 Medimmune, Llc Treatment methods using ctla-4 and pd-1 bispecific antibodies
WO2024002074A1 (zh) * 2022-06-28 2024-01-04 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA209003A (en) 1921-03-01 Krogman Joseph Whiffletree connector
CA209004A (en) 1921-03-01 K. Kronlund Theodore Mattress
CA209012A (en) 1921-03-01 L. Lilly Thomas End gates for autotrucks
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CN100480269C (zh) 1997-04-07 2009-04-22 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CA2361553A1 (en) 1999-01-29 2000-08-03 Zhenping Zhu Antibodies specific to kdr and uses thereof
BR0013581A (pt) 1999-08-23 2002-07-02 Dana Faber Cancer Inst Inc Pd-1, um receptor para b7-4, e usos para isto
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
WO2003075840A2 (en) 2002-03-04 2003-09-18 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
MX2007006057A (es) 2004-11-18 2007-12-10 Imclone Systems Inc Anticuerpos contra receptor de factor de crecimiento endotelial vascular-1.
EP2161336B2 (en) 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
ES2616355T3 (es) 2007-06-18 2017-06-12 Merck Sharp & Dohme B.V. Anticuerpos para el receptor humano de muerte programada PD-1
EP2614837A1 (en) 2007-11-09 2013-07-17 Affitech Research AS Anti-VEGF antibody compositions and methods
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
KR20180089573A (ko) 2008-12-09 2018-08-08 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
KR101740171B1 (ko) 2009-11-24 2017-05-25 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
CN103476943A (zh) 2011-03-10 2013-12-25 普罗维克图斯药品公司 用于增强治疗癌症的局部和全身性免疫调节疗法的组合
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
LT2734551T (lt) 2011-07-24 2018-04-10 Cure Tech Ltd. Humanizuotų imunomoduliuojančių monokloninių antikūnų variantai
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Also Published As

Publication number Publication date
RU2016148927A (ru) 2018-06-18
US20210324106A1 (en) 2021-10-21
US20170158776A1 (en) 2017-06-08
MX2022004000A (es) 2022-04-26
EP3142697A1 (en) 2017-03-22
KR20230144099A (ko) 2023-10-13
BR112016026559A8 (pt) 2021-07-13
EP3760229A3 (en) 2021-04-07
CA2949121A1 (en) 2015-11-19
KR20170003692A (ko) 2017-01-09
US20180319892A1 (en) 2018-11-08
WO2015176033A1 (en) 2015-11-19
CN115590953A (zh) 2023-01-13
BR112016026559A2 (pt) 2017-08-15
JP2017515859A (ja) 2017-06-15
EP3760229A2 (en) 2021-01-06
RU2695332C2 (ru) 2019-07-23
RU2016148927A3 (es) 2019-01-10
CN106714839A (zh) 2017-05-24

Similar Documents

Publication Publication Date Title
MX2022004000A (es) Uso de un anticuerpo de muerte anti-programada 1 (anti-pd-1) en combinacion con una quimioterapia doble a base de platino (pt-dc) para el tratamiento de cancer de pulmon.
EP3572430A3 (en) Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
MX2021008053A (es) Metodos para monitorear y terapias para usarse en tratar el cancer.
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
BR112018011029A2 (pt) métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
MX2018007756A (es) Anticuerpos anti-cd20/anti-cd3 biespecificos para tratar leucemia linfoblastica aguda.
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
PH12017502270A1 (en) Combination therapy for the treatment of cancer
SG10201810615VA (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer
MY190324A (en) Anti-pd-1 antibodies and compositions
PH12016502064A1 (en) Human antibodies to middle east respiratory syndrome-coronavirus spike protein
EP4386005A3 (en) Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
MX2021009852A (es) Anticuerpos humanos para pd-1.
MX2020010604A (es) Terapia de combinacion anticancer con anticuerpo antagonista del grupo de diferenciacion 73 (cd73) y anticuerpo antagonista del eje proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1).
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
MX2022002682A (es) Anticuerpos anti-cd73.
EA201990374A1 (ru) Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков
AU2017293423A8 (en) Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
MX2017007097A (es) Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
ZA201907754B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
BR112022001037A2 (pt) Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5